Shilpa Medicare’s marketing partner launches BORUZU in US market

03 Apr 2025 Evaluate

Shilpa Medicare’s marketing partner -- Amneal Pharmaceuticals has launched BORUZU, (Bortezomib for injection3.5mg/1.4ml), a new presentation of bortezomib for ready-to-use subcutaneous administration or intravenous (IV) administration in the U.S. market This new ready-to-use oncology product reduces the compounding preparation steps typically required with administration The product has already been granted permanent J-code by U.S. Centers for Medicare & Medicaid Services (CMS).

BORUZU (bortezomib injection), a proteasome inhibitor, is used for the treatment of multiple myeloma and mantle cell lymphoma. This product references the branded product Velcade, a lyophilized powder requiring reconstitution before use. Shilpa developed the molecule and Amneal will manufacture and commercialize the product. 

Shilpa Medicare produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications.


Shilpa Medicare Share Price

643.55 34.45 (5.66%)
08-Apr-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1688.75
Dr. Reddys Lab 1108.55
Cipla 1433.45
Lupin 1982.65
Zydus Lifesciences 859.55
View more..
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.
Please wait your portfolio is updating...